134 results
8-K/A
EX-10.1
vn9dy 33z38cpvy
2 Feb 24
Departure of Directors or Certain Officers
4:49pm
8-K
EX-99.1
v2jru 7uj99
19 Jan 24
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
5:14pm
8-K
kfeucc wd06v4
19 Jan 24
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
5:14pm
424B5
tlnoo4r1rnn81
17 Jan 24
Prospectus supplement for primary offering
7:18pm
8-K
EX-10.1
8eco 5wr5
16 Jan 24
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
5:18pm
8-K
3674woos1tapt
16 Jan 24
Vaxart, Inc. Announces Management Change
9:19am
8-K
EX-99.1
lwn9 jmt01jdieh
6 Sep 23
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
4:43pm
8-K
sutmrgh t16vu918
26 Jul 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:20pm
8-K
EX-99.1
ds8y th5ha70l63wxs
10 Jul 23
Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate
4:12pm
8-K
EX-1.1
107widyu
8 Jun 23
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
4:27pm
8-K
EX-99.1
cf09 99u5sro2l
6 Jun 23
No Vaccine Related Serious Adverse Events (SAEs) reported to date
8:07am